Myriad Genetics (MYGN) Tops Q4 EPS by 4c

Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.30, $0.04 better than the analyst estimate of $0.26. Revenue for the quarter came in at $200.5 million versus the consensus estimate of $193.74 million.

GUIDANCE:

Myriad Genetics sees FY2018 EPS of $1.00-$1.05. Myriad Genetics sees FY2018 revenue of $750-770 million, versus the consensus of $1.01 and $764.72 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance
• Goldman Sachs Starts Contemporary Amperex Technology Co Ltd (300750:CH) at Buy
• First Majestic raises 2026 output guidance after Q2 silver, gold gains